Solid tumor
Conditions
Interventions
Test group:Surufatinib ± chemotherapy ± IO
Sponsors
Fengxian People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =18 years old, both sexes, volunteer to participate in the trial and sign informed consent; 2. Advanced solid tumors confirmed by pathology; Including non-small cell lung cancer, small cell lung cancer, esophageal cancer, gastric cancer (including gastroesophageal junction adenocarcinoma), colorectal cancer, biliary tract cancer, liver/pancreatic cancer, etc. 3. Patients who failed or could not tolerate standard treatment; 4.ECOG score: 0-3; 5. At least one CT measurable lesion according to RECIST 1.1 criteria; 6. Expected survival for at least 3 months. 7. Investigator assessment of benefit; 8. All subjects voluntarily participated in the study and signed the informed consent form (ICF); 9. Good compliance is expected, and the efficacy and adverse reactions can be followed up according to the protocol.
Exclusion criteria
Exclusion criteria: 1. Patients allergic to surufatinib; 2. Patients with severe allergic history or allergic constitution; 3. Pregnant or lactating women; 4. Subjects with dysphagia or known drug malabsorption; 5. Patients who have participated in other clinical trials and have not discontinued the trial; 6. Major surgical treatment, open biopsy, or significant traumatic injury within 28 days before grouping (combined with clinical assessment); 7. Patients whose imaging showed that the tumor had invaded the important blood vessels or the investigator judged that the tumor was likely to invade the important blood vessels during the follow-up study, causing fatal hemorrhage; 8. Patients with any constitutional sign or history of bleeding regardless of severity; Patients with unhealed wounds, ulcers, or fractures who experienced any bleeding or bleeding event =CTCAE grade 3 within 4 weeks before enrollment; Patients with previous arterial/venous thrombosis events within 9.6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism; 10. Have a history of psychotropic drug abuse and cannot quit or have mental disorders; 11. Other conditions considered by the investigator to be inappropriate for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactXiuping Du
Fengxian People's Hospital
Outcome results
None listed